20.1 Polyclonal and Monoclonal Antibody Production

Antibody Production and Applications

Antibodies are among the most versatile tools in both diagnostics and therapeutics. The key distinction you need to know is between polyclonal antibodies, which recognize multiple epitopes on an antigen, and monoclonal antibodies, which target a single specific epitope. How each type is produced directly determines its strengths, limitations, and best uses in the lab and clinic.

Monoclonal vs. Polyclonal Antibodies

Polyclonal antibodies are produced by many different B cell clones responding to the same antigen. Because each clone targets a different epitope, the resulting serum contains a mixture of antibodies that bind the antigen at multiple sites.

To produce them, you immunize an animal (commonly a rabbit, goat, or horse) with the target antigen, wait for an immune response, then collect the serum. That serum contains the polyclonal antibody mixture. This approach is relatively quick and inexpensive, and the multi-epitope recognition makes polyclonal antibodies good at detecting antigens even if one epitope is partially hidden or altered.

Common applications include immunohistochemistry, ELISA (Enzyme-Linked Immunosorbent Assay), and Western blotting.

Monoclonal antibodies come from a single B cell clone, so every antibody molecule is identical and binds the same epitope. This gives them exceptional specificity and consistency between batches.

Production relies on hybridoma technology:

1. Immunize a mouse with the target antigen.
2. Harvest B cells from the mouse's spleen.
3. Fuse those B cells with myeloma cells (immortal tumor cells) to create hybridomas, hybrid cells that both produce antibody and divide indefinitely.
4. Screen the hybridomas to find the clone producing the desired antibody.
5. Culture that clone and collect the monoclonal antibody.

The myeloma fusion step is critical because normal B cells die quickly in culture. Hybridomas solve that problem by combining antibody production with unlimited growth.

Applications include:

• Diagnostic tests: pregnancy tests, cancer biomarker detection
• Targeted cancer therapies: rituximab (targets CD20 on B cell lymphomas), trastuzumab (targets HER2 in breast cancer)
• Autoimmune disease treatment: infliximab (neutralizes TNF-α in rheumatoid arthritis and Crohn's disease)

Antibody Cross-Reactivity in Diagnostics

Cross-reactivity occurs when an antibody binds an epitope on a non-target antigen because that epitope is structurally similar to the intended target. This is a real problem in diagnostic testing.

It can cause issues in two directions:

• False positives: The antibody binds a non-target antigen, producing a signal where there shouldn't be one. This can lead to unnecessary treatment or follow-up testing.
• False negatives: If cross-reactive binding ties up antibodies or competes with the true target, the test may underdetect the actual antigen, leading to missed diagnoses.

In formal terms, cross-reactivity reduces both the specificity (the ability to correctly identify people without the condition) and the sensitivity (the ability to correctly identify people with the condition) of a diagnostic assay. Monoclonal antibodies generally have less cross-reactivity than polyclonal antibodies because they target a single, well-defined epitope.

Production of Humanized Monoclonal Antibodies

Mouse-derived monoclonal antibodies work well in the lab, but when you inject them into a human patient, the human immune system often recognizes them as foreign and mounts a response against them. This is called immunogenicity, and it reduces the drug's effectiveness and can cause adverse reactions.

Humanized monoclonal antibodies solve this by replacing most of the mouse protein sequences with human ones, keeping only the parts that actually bind the target.

The production process:

1. Identify the CDRs: The complementarity-determining regions (CDRs) are the small loops within the antibody's variable region that make direct contact with the antigen. These are the parts you want to keep from the original mouse antibody.
2. Graft CDRs onto a human framework: Take a human antibody and swap in the mouse CDRs. The result is an antibody that's mostly human protein but retains the mouse antibody's binding specificity.
3. Express in mammalian cells: The engineered gene is inserted into a mammalian cell line (such as CHO cells) for production, since mammalian cells add the correct post-translational modifications.
4. Purify and characterize: The antibody is isolated and tested to confirm it binds the target with adequate affinity and has the expected structure.

Clinical uses span several major areas:

• Cancer immunotherapy: Antibodies targeting immune checkpoint molecules like PD-1 or CTLA-4 release the brakes on the immune system, helping it recognize and destroy tumor cells.
• Autoimmune and inflammatory diseases: Antibodies that neutralize pro-inflammatory cytokines such as TNF-α or IL-6 reduce the excessive immune response that drives tissue damage.
• Infectious disease: Antibodies can neutralize pathogens directly (e.g., palivizumab against respiratory syncytial virus, raxibacumab against anthrax toxin), providing passive immunity to high-risk patients who can't mount an adequate response on their own.

Key Terms

• Antigen: A substance (typically a foreign protein or polysaccharide) that triggers an immune response and can be specifically recognized by antibodies.
• Epitope: The specific part of an antigen that an antibody binds to. A single antigen can have multiple epitopes.
• Immunization: Exposing an animal (or person) to an antigen to stimulate antibody production.
• Affinity: The strength of binding between one antibody and its specific epitope. Higher affinity means tighter, more stable binding.
• Specificity: The ability of an antibody to bind its intended target and not other molecules.
• Hybridoma: A cell created by fusing an antibody-producing B cell with an immortal myeloma cell, combining antibody production with indefinite growth in culture.